Analysts Reaffirm Neutral Rating for BAT Stock

BAT by 2FIRSTS.ai
Dec.18.2023
Analysts Reaffirm Neutral Rating for BAT Stock
JPMorgan Chase & Co. reaffirms neutral rating on British American Tobacco stock, with a target price of £27.

According to a report from MarketBeat, JPMorgan Chase & Co., the multinational investment bank, has reiterated its neutral rating for British American Tobacco stock. They have set a target price of £27 (approximately $33.89) for the stock.

 

Other research analysts have also recently issued research reports on the company. Royal Bank of Canada has reconfirmed its industry performance rating for British American Tobacco stocks and set a price target of £35 (approximately $43.94) in its research report on November 24th.

 

Jefferies Financial Group has once again issued a buy rating and set a price target of £41 (approximately $51.47) in their research report on November 15th.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Germany OLG Cologne: Touchscreen Vape Use Violates Driving “Phone Ban”
Germany OLG Cologne: Touchscreen Vape Use Violates Driving “Phone Ban”
Germany’s OLG Cologne ruled that adjusting an e-cigarette touchscreen while driving violates the “phone ban” under road traffic law. The driver, caught changing vape settings on the highway, was fined €150 and received one penalty point, as the court said such actions pose significant distraction risks.
Oct.27 by 2FIRSTS.ai
Melaka Cracks Down on Unlicensed Vape Retailers with Fines and Seizures
Melaka Cracks Down on Unlicensed Vape Retailers with Fines and Seizures
Melaka’s local authorities are intensifying enforcement against unlicensed e-cigarette retailers by issuing notices, imposing fines, and seizing illegal products. State executive councillor Datuk Ngwe Hee Sem said only premises meeting the required conditions will be granted trading licences under the Licensing of Trades (Local Authorities) By-Laws 2010.
Dec.10 by 2FIRSTS.ai
Geek Bar Launches New Pulse Models in the U.S.: Thermochromic Design, Core Specs Intact
Geek Bar Launches New Pulse Models in the U.S.: Thermochromic Design, Core Specs Intact
U.S. vape retailer VapeSourcing has listed GEEKBAR Pulse 15K/25K Thermal Edition products, currently marked “Coming Soon.” Both models retain the core Pulse-series configuration but adopt a thermochromic, color-changing shell; the Pulse 15K is flagged as GEEKBAR’s first device to use this finish.
Nov.04 by 2FIRSTS.ai
Canadian Media Investigation: BAT’s Nicotine Pouch ZONNIC Sparks Ongoing Controversy as Regulatory Gaps in Canada Come Under Scrutiny
Canadian Media Investigation: BAT’s Nicotine Pouch ZONNIC Sparks Ongoing Controversy as Regulatory Gaps in Canada Come Under Scrutiny
Canadian outlet Rebel News released a long-form video report examining Canada’s regulatory framework for nicotine pouches, market dynamics, and the approval process of ZONNIC, a product of BAT subsidiary Imperial Tobacco Canada. The report highlights issues involving youth access, regulatory gaps, black-market activity, retailer feedback, and company responses. This article summarizes key points based on the video.
Dec.02 by 2FIRSTS.ai
Product | 2Firsts Exclusive: Breaking Down Pachamama 25K, CHUC’s First U.S.-Made Factory Product
Product | 2Firsts Exclusive: Breaking Down Pachamama 25K, CHUC’s First U.S.-Made Factory Product
U.S. e-cigarette company Charlie’s has brought its first domestic manufacturing facility online, launching the disposable Pachamama 25K, which will initially roll out to 300 retail stores in Texas. The device features a 20 ml e-liquid capacity with 5% nicotine, three power modes and a built-in 1000 mAh battery, and is advertised to deliver up to 25,000 puffs.
Dec.02 by 2FIRSTS.ai
 Breaking News | FDA Adds ON! Plus Nicotine Pouches to PMTA-Authorized List
Breaking News | FDA Adds ON! Plus Nicotine Pouches to PMTA-Authorized List
The U.S. Food and Drug Administration (FDA) has added ON! Plus nicotine pouch products to its list of authorized products, disclosing that the brand has received Marketing Granted Orders (MGO) through the Premarket Tobacco Product Application (PMTA) pathway. The update makes ON! Plus the second nicotine pouch brand authorized via PMTA, following ZYN. As of publication, the FDA had not issued a separate press release on the decision.
News
Dec.20